[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"aortic-aneurysm-and-dissection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:aortic-aneurysm-and-dissection":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,38,79,107,133,152,175,207],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":4},"100053943","outcomes-of-left-subclavian-artery-revascularization-strategies-during-zone-2-thoracic-endovascular-aortic-repair-100053943",false,"NCT07697820","Outcomes of Left Subclavian Artery Revascularization Strategies During Zone 2 Thoracic Endovascular Aortic Repair","Inclusion Criteria:\n\nPatients ≥18 years Undergoing TEVAR with proximal landing in zone 2 whether acute or chronic type B aortic dissection (TBAD), thoraco-abdominal aortic aneurysm (TAAA), penetrating aortic ulcer (PAU) or intramural hematoma (IMH).\n\n• Treatment with one of the following:\n\n* Single-branched stent grafts\n* In-situ fenestration (e.g. ISLF ± stent)\n* Chimney\u002Fperiscope graft techniques\n* Physician-modified endografts (PMEGs)\n* Carotid-subclavian bypass, carotid-axillary bypass, or subclavian transposition\n\nExclusion Criteria:\n\n* • Non revascularized left subclavian artery.\n\n  * Zone 0 or 1 procedures\n  * Multi-vessel arch debranching\n  * Blunt traumatic aortic injury (BTAI)\n  * Incomplete imaging or follow-up data","ALL","18 Years",{"count":18,"type":19},50,"ESTIMATED","INTERVENTIONAL",[22],"NA","Intentional coverage of left subclavian artery (LSA) is often necessary during thoracic endovascular aortic repair (TEVAR) to secure an adequate proximal landing zone. However, this may impair blood flow to vital vascular territories with increased risk of stroke, spinal cord ischemia and upper limb ischemia.\n\nCurrent recommendations from the Society for Vascular Surgery (SVS) and European Society for Vascular Surgery (ESVS) support the consideration of LSA revascularization in patients undergoing elective TEVAR with anticipated LSA coverage. In contrast, management in the acute setting is more complex and requires an individualized approach based on clinical urgency and anatomical factors. Revascularization is generally recommended in high-risk clinical scenarios, including patients with dominant left vertebral circulation, compromised or occluded contralateral vertebral artery, an incomplete circle of Willis, or variant vertebral anatomy such as a hypoplastic left vertebral artery terminating in the posterior inferior cerebellar artery or an isolated vertebral artery. Additional indications include prior LIMA grafting, the presence of upper limb dialysis access, anticipated extensive aortic coverage, or an aberrant right subclavian artery in which both subclavian origins may be compromised.\n\nRevascularization techniques encompass both open surgical and endovascular approaches. Surgical options include carotid-subclavian bypass, carotid-axillary bypass, and subclavian transposition, while endovascular methods involve branched or fenestrated endografts, chimney and periscope grafts, as well as in situ fenestration. Although surgical techniques provide durable long-term patency, they are associated with a risk of local complications. Endovascular approaches are minimally invasive; however, they may be associated with an increased risk of endoleaks.\n\nAnatomical factors also play a central role in determining both the feasibility and outcomes. Preoperative assessment using computed tomography angiography is essential to evaluate aortic arch morphology, proximal landing zone characteristics, branch vessel orientation, and access vessel suitability. In addition, the spatial relationship between the left common carotid artery (LCCA) and LSA, including minimum inter-vessel distances, directly influences the feasibility of branched or fenestrated endografts. Also branch vessel anatomy is equally critical, as LSA diameter, vertebral artery origin, and vessel length determine the suitability for branch incorporation or fenestration techniques. Furthermore, access-related anatomical constraints, particularly iliofemoral vessel diameter and calcification, may significantly limit device delivery.",[25],"Aortic Aneurysm and Dissection","NOT_YET_RECRUITING","2026-07-10",{"date":29,"type":30},"2026-07-13","ACTUAL",{"date":32,"type":19},"2026-10-01",{"date":34,"type":19},"2028-12-01",{"name":36,"class":37},"Assiut University","OTHER",{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":20,"phases":48,"briefSummary":49,"conditions":50,"keywords":56,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":78},"100598968","a-study-to-evaluate-the-safety-and-effectiveness-of-the-rapidlink-device-when-used-in-patients-undergoing-an-open-surgical-procedure-to-repair-the-aorta-100598968","NCT07078383","A Study to Evaluate the Safety and Effectiveness of the Rapidlink Device When Used in Patients Undergoing an Open Surgical Procedure to Repair the Aorta","Evaluation of the Rapidlink Device for Use in the Repair or Replacement of the Supra-Aortic Vessels During an Open Surgical Procedure of the Thoracic Aorta","RAPID","Inclusion Criteria:\n\n* Patient is aged 18 years or over on date of consent\n* Written informed consent (from patient or a legally authorized representative) to participate in study, documenting willingness and ability to comply with all study procedures and study visits (unless an exemption for emergency cases has been IRB \u002F EC approved)\n* Patient's need for open surgical repair of the thoracic aorta using a Gelweave graft or a Thoraflex Hybrid device (AnteFlo or Plexus) in line with the applicable IFU\n* Anticipated need to use Rapidlink for the repair or replacement of the LSA, LCCA and\u002For IA during the open surgical repair\n* Patient has an 8-15 mm inner diameter (target SAV)\n* The diameters of the patient's target supra-aortic vessel(s), fall within the ranges specified in the IFU\n\nExclusion Criteria:\n\n* Patient does not have a clear landing zone equal to the implantable stent length which is free from stenosis, calcification or thrombus.\n* Patient does not have a sealing zone free from tortuosity.\n* Patient has significant angulation (\\>79° with an internal radius of less than 6mm) for the full implantable stent length\n* Patient cannot receive anticoagulation \u002F antiplatelet therapy during or after the index procedure as per the protocol\n* Patient has uncontrolled hypercoagulation\n* Patient has a condition which may compromise or prevent the necessary imaging requirements\n* Patient has anatomic variants which would compromise circulation to the first branch off the target artery after placement of the Rapidlink device (unless planned and\u002For otherwise revascularized)\n* Patient is unfit for open surgical repair involving circulatory arrest per the study investigator\n* Patient has known sensitivity to polyester, nitinol, tantalum, or materials of bovine origin\n* Patient has a ruptured aorta\n* Patient has active endocarditis or an active infective disorder of the aorta\n* Patient has an active systemic infection that, in the opinion of the investigator, would compromise the outcome of the surgical procedure\n* Patient is enrolled in another active study and has received an investigational product (device, pharmaceutical or biologic) within 6 months prior to the date of the implant or has not reached the primary endpoint of the study\n* Patient is female and is pregnant or planning to become pregnant during the course of the study. Females of childbearing potential must use acceptable methods of contraception during the course of the study.\n* Patient has an uncorrectable bleeding anomaly\n* Patient has renal failure (defined as dialysis dependent or serum creatinine ≥2.5mg\u002FdL)\n* Patient has known sensitivity to radiopaque contrast agents that cannot be adequately pre-treated\n* Patient has a co-morbidity causing expected survival to be less than 1 year\n* Patient has any other medical, social or psychological problems that in the opinion of the investigator preclude them from receiving this treatment and the procedures and evaluations pre and post procedure\n* Patient has a known chronic aortic dissection involving the intended landing zone of the target supra-aortic vessel(s)",{"count":47,"type":19},150,[22],"The Goal of this Clinical Study is to evaluate the safety and effectiveness of the Rapidlink device in the repair or replacement of the supra-aortic vessels during open surgical repair of aortic disease affecting the thoracic aorta.\n\nThis study will collect information on patients who are already having surgery to repair their aorta and who will have Rapidlink device implanted into one or more of the aortic arch vessels.\n\nThe first 32 subjects enrolled will undergo left subclavian artery repair or replacement, only, with the Rapidlink device. After the 32nd subject, enrollment will proceed to include subjects undergoing any supra-aortic vessel (i.e., left subclavian artery, left common carotid artery, and\u002For innominate artery) repair or replacement with the Rapidlink device in a planned surgery.\n\nAfter the 32nd subject is enrolled in the main group, up to 30 subjects will undergo supra-aortic vessel (i.e., left subclavian artery, left common carotid artery, and\u002For innominate artery) repair or replacement with the Rapidlink device in an emergency setting.\n\nData will be collected before, during and after surgery including recovery at discharge, 30 days, 6 months, 1 and 2 years after the surgery.",[51,25,52,53,54,55],"Aortic Aneurysm","Aortic Diseases","Aneurysm of Aorta, Thoracic","Aneurysmal Disease","Aorta, Thoracic Pathologies",[57,58,59,60,61,62,63,64,65,66],"Vascular Prosthesis","Replacement or bypass of disease vessels","aneurysmal disease","Aortic branch vessels","Open aortic arch repair","aneurysm","dissection","Supra-aortic Vessels","Frozen Elephant Trunk","Left Subclavian Artery","RECRUITING","2026-07-01",{"date":70,"type":30},"2026-07-02",{"date":72,"type":30},"2025-12-19",{"date":74,"type":19},"2028-11",{"name":76,"class":77},"Vascutek Ltd.","INDUSTRY",22,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":20,"phases":86,"briefSummary":87,"conditions":88,"keywords":91,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":106},"100642433","effects-of-myofascial-release-on-cardiac-patients-after-median-sternotomy-100642433","NCT07649330","Effects of Myofascial Release on Cardiac Patients After Median Sternotomy","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Able to communicate verbally and follow instructions\n* Diagnosed by a physician with coronary artery disease, valvular disease, or aortic disease\n* Undergoing median sternotomy\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Presence of a cardiac pacemaker\n* Presence of a ventricular assist device (VAD)\n* Existing central nervous system disorders (e.g., hemorrhagic or ischemic stroke, spinal cord injury, traumatic brain injury)\n* Cognitive impairment or inability to understand\u002Ffollow instructions\n* Diagnosed with chronic obstructive pulmonary disease (COPD)\n* History of previous thoracic surgery\n* ICU stay longer than 14 days",{"count":18,"type":19},[22],"After deciding to join this study and signing the informed consent form, participants will undergo the following interventions:\n\nAll participants will receive a preoperative assessment (Tp) before surgery. Within five days after transferring from the ICU to the general ward, participants will receive a baseline assessment (T0). After completing seven sessions of myofascial release (MFR), a post-intervention assessment (T1) will be conducted.\n\nAssessments include maximum inspiratory pressure (MIP), maximum expiratory pressure (MEP), pulmonary function tests, mid- and lower-thoracic mobility, surface electromyography (sEMG) to measure diaphragmatic and sternocleidomastoid muscle activity, and pain scores. Pulmonary function tests include forced vital capacity (FVC), forced expiratory volume in one second (FEV1), FEV1\u002FFVC ratio, and maximum voluntary ventilation (MVV).\n\nParticipants will be randomly assigned to an intervention group or a control group. The intervention group will receive myofascial release therapy in addition to routine physical therapy in the general ward. Routine therapy includes daily physical therapy sessions such as out-of-bed activities, incentive spirometry training (Triflow), and functional exercises. The MFR intervention consists of three steps:\n\nThe therapist places both hands on the thoracic outlet, with the index and middle fingers above the clavicle.\n\nOne hand is placed on the anterior chest and the other hand parallel on the participant's back.\n\nBoth hands are placed on the anterolateral region of the thoracoabdominal diaphragm.\n\nDuring each step, participants are instructed to take 10 slow, deep breaths and direct airflow toward the therapist's hands. Each session lasts approximately 15 minutes, once daily, for seven sessions.\n\nThe control group will receive only routine physical therapy (out-of-bed activities, incentive spirometry, and functional exercises) without additional myofascial release therapy.",[25,89,90],"Coronary Artery Disease (CAD)","Valve Heart Disease",[92,93,94,51,95,96],"Median Sternotomy","Cardiac Surgery","Coronary Artery Disease","Aortic Dissection","Valvular Heart Disease","2026-06-09",{"date":99,"type":30},"2026-06-16",{"date":101,"type":30},"2026-03-25",{"date":103,"type":19},"2027-09",{"name":105,"class":37},"Siou-Pin Huang",1,{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":115,"sex":15,"minAge":116,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":119,"phases":4,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":128,"leadSponsor":130,"locationsCount":132},"100626645","ai-care-artificial-intelligence-for-cardiovascular-analysis-and-risk-evaluation-100626645","NCT07438327","AI-CARE: Artificial Intelligence for Cardiovascular Analysis and Risk Evaluation","AI-CARE: Artificial Intelligence for Cardiovascular Analysis and Risk Evaluation - Clinical Evaluation of Aorta Automated Imaging Measurement (Aorta AIM)","AI-CARE","* Adults ≥22 years at time of imaging\n* Studies performed 1 Jan 2016 - 31 August 2025\n* CT imaging of the whole, thoracic, or abdominal aorta, with or without contrast enhancement, acquired with any gating protocol (including non-gated)\n* Slice thickness ≤ 3mm\n* CT imaging in which truncation creates discontinuity within a targeted aortic region, preventing reliable diameter measurement (e.g., cardiac-focused CT acquisitions where an incomplete or absent aortic arch creates discontinuity between the aortic root and the descending thoracic aorta)\n\n  o Partial aortic coverage is not grounds for exclusion. Where truncation affects individual regions, only those specific regions will be excluded from analysis; remaining fully captured regions will be retained for measurement.\n* Metal implants \\\u003C5cm from aorta (e.g. thoracic stent)\n* Prior aortic surgery\n* Severe motion artifacts (e.g. \\>3mm vessel blurring)\n* Congenital aortic anomalies (e.g. coarctation, vascular rings)\n* Post-traumatic aortic repairs\n* The patient opted out of having their data used for medical research before the date of cross-referencing by the site team",true,"22 Years",{"count":118,"type":19},250,"OBSERVATIONAL","This study will test how well an artificial intelligence (AI) software called Aorta AIM measures the size of the aorta (the body's main blood vessel) from CT scans. The aorta can become enlarged over time, which may lead to serious health problems. Doctors need to measure the aorta accurately to monitor patients and decide on treatment.\n\nCurrently, doctors measure the aorta manually on CT scans, which takes time and can vary between different doctors. Aorta AIM is designed to measure the aorta automatically and consistently.\n\nIn this study, researchers will compare Aorta AIM's measurements to those made by experienced radiologists or cardiologists (doctors who specialize in reading medical images). The study will use CT scans that have already been taken as part of routine medical care - no additional scans or procedures are needed.\n\nThe study will include approximately 250 participants across multiple hospitals in Brazil and the United States. Participants will be adults who have had a chest or abdominal CT scan that shows their aorta.\n\nThe main goals are to:\n\n* Check if Aorta AIM measures the aorta as accurately as radiologists\n* See if Aorta AIM can help doctors work more efficiently\n* Evaluate if the software works well in different hospital settings and with different types of patients\n\nThis research may help improve how doctors monitor aortic disease and make treatment decisions in the future. There are no risks to participants since the study only uses existing medical images.",[51,122,25,123],"Aortic Aneurysm Abdominal","Aortic Aneurysm, Thoracoabdominal","2026-03-31",{"date":126,"type":30},"2026-04-06",{"date":124,"type":30},{"date":129,"type":19},"2026-09-05",{"name":131,"class":77},"Aiatella Oy",3,{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":115,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":119,"phases":4,"briefSummary":141,"conditions":142,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":106},"100625399","multidisciplinary-analysis-by-morphological-and-mechanical-evaluation-of-the-aortic-wall-in-patients-undergoing-cardiac-surgery-100625399","NCT07422129","Multidisciplinary Analysis by Morphological and Mechanical Evaluation of the Aortic Wall in Patients Undergoing Cardiac Surgery.","Multidisciplinary Analysis by Morphological and Mechanical Evaluation of the Aortic Wall in Patients With Aortic Disease, Undergoing Aortic Cardiac Surgery, vs Patients Without Aortic Disease","Inclusion Criteria:\n\n* Patients undergoing surgery including ascending aorta replacement at our Department and\u002For heart transplantation\n\nExclusion Criteria:\n\n* Patients with biological hazard (HBC\u002FHIV +)",{"count":118,"type":19},"Surgical indication in patients suffering from Ascending aorta aneurysm is currently based mainly on the maximum diameter of the aortic dilatation and on the yearly growth rate. Several clinical preoperative patients characteristics have been, potentially, correlated to impaired mechanical characteristics of aortic wall, and therefore to an increased risk of rupture and or dissection. On other hands, such suppositions have been never confirmed, as a full characterization of the mechanical behaviour of the ascending aortic tissue, especially in case of aneurysm, has not been fully clarified yet. Objective of this observational study is to better elucidate, using direct in vivo evaluation, the mechanical characteristics of the aortic wall in patients with ascending aorta diseases. Our study will have a further peculiar characteristic as we have the intention of compare such mechanical characteristics to those of patients, without known aortic diseases, undergoing heart transplantation. Potential correlation between, directly measured mechanical characteristics of the aortic wall, and preoperative parameters (anagraphic patients characteristics, clinical data and diagnostic tests) will be also investigated.",[51,25],"2026-02-12",{"date":145,"type":30},"2026-02-19",{"date":147,"type":30},"2015-03-24",{"date":149,"type":19},"2027-12-31",{"name":151,"class":37},"Fondazione IRCCS Policlinico San Matteo di Pavia",{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":159,"enrollmentInfo":160,"targetDuration":4,"studyType":20,"phases":162,"briefSummary":163,"conditions":164,"keywords":165,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":172,"leadSponsor":173,"locationsCount":5},"100622342","ai-assisted-subtyping-directed-precision-treatment-in-acute-aortic-dissection-100622342","NCT07382375","AI-assisted Subtyping-directed Precision Treatment in Acute Aortic Dissection","AI-assisted Immunoinflammatory Subtyping-Directed Precision Treatment in Acute Aortic Dissection: A Multicenter RCT-based Exploration","Inclusion Criteria:\n\n1. Confirmed diagnosis of acute aortic dissection by contrast-enhanced Computed Tomography Angiography (CTA) or Magnetic Resonance Angiography (MRA);\n2. Planned emergency surgical treatment (including open surgery and endovascular repair);\n3. Aged 18-80 years old, regardless of gender;\n4. Time from onset to hospital admission ≤ 72 hours;\n5. Signed informed consent form by the patient or their authorized agent, with willingness to cooperate with the follow-up of the study.\n\nExclusion Criteria:\n\n1. Complicated with underlying diseases that affect immunoinflammatory status, such as severe infections (e.g., sepsis, infective endocarditis), autoimmune diseases, malignant tumors, chronic liver diseases, and chronic kidney diseases (uremic stage);\n2. Long-term use of immunosuppressants or glucocorticoids before surgery (continuous use for ≥ 2 weeks);\n3. Pregnant or lactating women;\n4. Patients with mental disorders or cognitive dysfunction who cannot cooperate with the study.","80 Years",{"count":161,"type":19},300,[22],"Aortic dissection has acute onset and high mortality, with immunoinflammatory response driving lesion progression. Current perioperative anti-inflammatory therapies are mostly empirical and poorly targeted, and AI-assisted typing lacks a complete clinical translation pathway. This study integrates multi-dimensional data to construct an AI immunoinflammatory subtyping system, enabling rapid subtyping and establishing a \"subtyping-target-treatment\" closed loop for emergency needs. Using a prospective multicenter RCT, 300 patients are randomly divided into two groups: the experimental group receives subtyping-based precision therapy, while the control group uses empirical strategies (treatment of physician's choice). It observes 7-day postoperative SOFA score, SIRS and other prognostic indicators to provide evidence-based support for precision treatment.",[25],[166,167],"inflammation","immune","2026-01-28",{"date":170,"type":30},"2026-02-02",{"date":149,"type":19},{"date":149,"type":19},{"name":174,"class":37},"Nanjing Medical University",{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":182,"enrollmentInfo":183,"targetDuration":4,"studyType":20,"phases":184,"briefSummary":185,"conditions":186,"keywords":190,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":106},"100541926","antibacterial-tactics-based-on-presepsin-level-in-thoracic-aorta-surgery-patients-100541926","NCT06336213","Antibacterial Tactics Based on Presepsin Level in Thoracic Aorta Surgery Patients","Changes in Antibacterial Therapy Based on Perioperative Dynamics of Presepsin During Reconstructive Thoracic Aorta Surgery","Inclusion Criteria:\n\nThoracic aorta aneurysm\u002Fdissection\n\nExclusion Criteria:\n\nBlood sample hemolysis","75 Years",{"count":18,"type":19},[22],"According to the literature, presepsin was recommended not only as an effective indicator in the diagnosis of sepsis in intensive care units, but also as a reliable prognostic marker of postoperative inflammatory processes in cardiac surgery. Previous study carried out in Petrovsky NRCS related to biomarkers in cardiac surgery and presepsin in particular showed good sensitivity in infection complications prognosis.",[25,187,188,189],"Cardiac Valve Disease","Thoracic Aortic Aneurysm","Thoracic Aortic Dissection",[191,192,193,194,195,196,197,198],"biomarkers","presepsin","complications","aortic arch","aorta","aortic aneurysm","ascending aorta","cardiac surgery",{"date":200,"type":30},"2026-01-29",{"date":202,"type":30},"2024-01-23",{"date":204,"type":19},"2027-02-15",{"name":206,"class":37},"Petrovsky National Research Centre of Surgery",{"id":208,"slug":209,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":211,"acronym":4,"eligibilityCriteria":212,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":213,"targetDuration":4,"studyType":119,"phases":4,"briefSummary":215,"conditions":216,"keywords":217,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":226,"locationsCount":106},"100601722","a-prospective-study-of-discomfort-symptoms-in-patients-with-aortic-disease-after-endovascular-intervention-100601722","NCT07114185","A Prospective Study of Discomfort Symptoms in Patients With Aortic Disease After Endovascular Intervention","Inclusion Criteria:\n\n1. Diagnosed with thoracoabdominal aortic disease\n2. Patients who underwent endovascular treatment of the thoracoabdominal aorta via the femoral artery approach\n\nExclusion Criteria:\n\n1. Aortic disease caused by infection\n2. Aortic disease caused by trauma\n3. Aortic disease treated by open abdominal surgery\n4. Presence of systemic diseases uncontrollable by current medical standards (e.g., severe cardiac, pulmonary or hepatic dysfunction; advanced malignancy; cachexia; refractory severe coronary artery disease symptoms; coagulation disorders caused by genetic diseases, etc.)\n5. Patients who have undergone endovascular aortic treatment via femoral artery access prior to this procedure due to other diseases (not related to the current aortic disease)",{"count":214,"type":19},120,"The incidence and severity of post-procedural discomfort were evaluated in patients undergoing endovascular repair for aortic disease across six symptom-related dimensions: immobilization-related issues, puncture site discomfort, adhesive-induced skin reactions, post-stent implantation syndrome, impairment in self-care ability, and physical\u002Fpsychological stress responses.",[25],[218,219],"nursing","postoperative complication management","2025-08-03",{"date":222,"type":30},"2025-08-11",{"date":224,"type":19},"2026-01-01",{"date":149,"type":19},{"name":227,"class":37},"First Affiliated Hospital of Zhejiang University"]